|Day Low/High||44.95 / 45.54|
|52 Wk Low/High||44.30 / 68.22|
Three quarters of Bristol-Myers Squibb shareholders vote to approve the deal with Celgene, paving the way for the largest pharmaceutical takeover in history.
Bristol-Myers Squibb Company (NYSE: BMY) today announced that its shareholders voted to approve the issuance of shares of Bristol-Myers Squibb common stock in connection with the Company's pending merger with Celgene Corporation (NASDAQ:CELG) at the...
Bristol-Myers Squibb Company (NYSE: BMY) today announced results from pooled analyses of survival data from four studies (CheckMate -017, -057, -063 and -003; n=664) in patients with previously-treated advanced non-small cell lung cancer (NSCLC) who were...
The myriad names in oncology have been the hottest area for acquisitions along with gene therapy.
Celgene surges Friday after an influential shareholder advisory group recommend investors vote in favor of the cancer drug specialist's takeover by Bristol-Myers Squibb Co. while a key activist dropped its opposition to the $74 billion deal.
Bristol-Myers Squibb Company (NYSE:BMY) today issued the following statement regarding Celgene's (NASDAQ:CELG) settlement with Lotus Pharmaceutical Co.
NEW YORK, March 29, 2019 /PRNewswire/ -- Starboard Value LP (together with its affiliates, "Starboard"), a shareholder of Bristol-Myers Squibb Company ("Bristol-Myers" or the "Company") (NYSE:BMY), today provided the following statement on its investment...
Bristol-Myers Squibb Company (NYSE:BMY) today announced that independent proxy advisory firms Institutional Shareholder Services ("ISS") and Glass Lewis & Co.
Lots of IPOs and innovation will reward investors who do their homework, Jim Cramer says.
Starboard Asks Shareholders to NOT Allow Bristol-Myers to Bet the Company on a Highly-Risky and Likely Value-Destructive Acquisition
The most recent short interest data has been released for the 03/15/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
The biotech sector isn't for the faint of heart, but these two companies issued promising news this week.
Bristol-Myers Squibb says Tuesday the Federal Trade Commission has requested information related to its planned $74 billion takeover of cancer drug company Celgene.
Jim Cramer takes a look at Bristol-Myers Squibb, Xilinx, Nieslen, Realty Income, W&T Offshore and more.
Apple couldn't do much to hold back the bears today, but Jim Cramer says the company's services segment is the most important thing and he's more than happy with it.
Bristol-Myers Squibb Company's (NYSE:BMY) Board of Directors today sent an open letter to the Company's shareholders regarding the previously announced definitive merger agreement with Celgene Corporation (NASDAQ:CELG).
Bristol-Myers Squibb trades blows with activist investor Starboard Value Tuesday as the pair issues competing presentations linked to the pharmaceutical group's planned $74 billion takeover of cancer drug specialist Celgene.
Jim Cramer thinks that Bristol-Myer's deal with Celgene is a positive thing, despite Starboard's resistance.
Bristol-Myers, Tilray, and Elon Musk are some of the top headlines in business news Tuesday. Here's what Jim Cramer's watching.
Here's what you need to know about Tilray's earnings, Elon Musk's fight with the SEC and Bristol-Myers fight with Starboard over Celgene. Jim Cramer talks the markets
Mails Definitive Proxy Materials and a BLUE Proxy Card for Shareholders to Vote AGAINST the Proposed Transaction at the Upcoming Special Meeting
Bristol-Myers Squibb Company (NYSE: BMY) today filed a new investor presentation with the Securities and Exchange Commission (SEC) in connection with its previously announced definitive merger agreement with Celgene Corporation (NASDAQ: CELG).
The Bristol-Myers Squibb- Pfizer Alliance today announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis ® (apixaban) versus vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation (NVAF) and recent acute coronary...
Nvidia and Mellanox have many common customers, and also a major common competitor in Intel.
The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of forty one cents ($0.
David Tepper's Appaloosa LP renews calls for changes at the top.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.